Biblio Discovery — Demo Discovery Service

7 hasil untuk "David Spragg"

Menampilkan 1–7 · 0,15 detik · RSS

  1. Artikel Jurnal

    Safety and efficacy of cryoballoon versus radiofrequency ablation for atrial fibrillation in elderly patients: A real-world evidence

    Tauseef Akhtar; Ryan Wallace; Usama A. Daimee dkk.

    Indian Pacing and Electrophysiology Journal, Vol. 22 No. 1 · 2022 · Inggris · DOAJ Scopus

    Background: There are limited data describing the experience of radiofrequency (RF) vs. cryoballoon (CB) ablation for atrial fibrillation (AF) among elderly patients in the United States. Methods: We conducted a retrospective analysis of patients ≥75 years of age undergoing index RF vs. CB ablation…

  2. Artikel Jurnal

    The Association of Pre-Existing Left Atrial Fibrosis with Clinical Variables in Patients Referred for Catheter Ablation of Atrial Fibrillation

    Jane Dewire; Irfan M. Khurram; Farhad Pashakhanloo dkk.

    Clinical Medicine Insights: Cardiology, Vol. 8s1 · 2014 · Inggris · DOAJ Scopus

    Introduction Atrial fibrillation (AF) recurrence after ablation is associated with left atrial (LA) fibrosis on late gadolinium enhanced (LGE) magnetic resonance imaging (MRI). We sought to determine pre-ablation, clinical characteristics that associate with the extent of LA fibrosis in patients…

    Juga tersedia di: DOAJ

  3. Artikel Jurnal

    The Virtual Inclusive Digital Health Intervention Design to Promote Health Equity (iDesign) Framework for Atrial Fibrillation: Co-design and Development Study

    Nino Isakadze; Nancy Molello; Zane MacFarlane dkk.

    JMIR Human Factors, Vol. 9 No. 4 · 2022 · Inggris · DOAJ Scopus

    BackgroundSmartphone ownership and mobile app use are steadily increasing in individuals of diverse racial and ethnic backgrounds living in the United States. Growing adoption of technology creates a perfect opportunity for digital health interventions to increase access to health care. To…

  4. Artikel Jurnal Teks lengkap

    Changes in QTc Interval in the Citalopram for Agitation in Alzheimer's Disease (CitAD) Randomized Trial

    Lea T. Drye; David Spragg; D. P. Devanand dkk.

    PLoS ONE, Vol. 9 No. 6 · 2014 · Inggris · PLOS Scopus

    Background: A Food and Drug Administration (FDA) safety communication in August 2011 warned that citalopram was associated with a dose dependent risk of QT prolongation and recommended dose restriction in patients over the age of 60 but did not provide data for this age group. Methods: CitAD was a…

    Juga tersedia di: DOAJ